Self-Assembly Engineering Nanodrugs Composed of Paclitaxel and Curcumin for the Combined Treatment of Triple Negative Breast Cancer

The clinical outcomes of triple-negative breast cancer (TNBC) chemotherapy are unsatisfactory. Water solubility and biosafety of chemo drugs are also major barriers for achieving satisfactory treatment effect. In this study, we have reported a combinational strategy by self-assembly engineering nano...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in bioengineering and biotechnology Vol. 9; p. 747637
Main Authors Zuo, Shuting, Wang, Zhenyu, An, Xianquan, Wang, Jing, Zheng, Xiao, Shao, Dan, Zhang, Yan
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 24.08.2021
Subjects
Bioengineering and Biotechnology
curcumin
nanodrug
paclitaxel
self-assembly
triple-negative breast cancer
paclitaxel
self-assembly
triple-negative breast cancer
nanodrug
curcumin
Online AccessGet full text

Cover

More Information
Summary:The clinical outcomes of triple-negative breast cancer (TNBC) chemotherapy are unsatisfactory. Water solubility and biosafety of chemo drugs are also major barriers for achieving satisfactory treatment effect. In this study, we have reported a combinational strategy by self-assembly engineering nanodrugs PC NDs, which were composed of paclitaxel (PTX) and curcumin (Cur), for effective and safe TNBC chemotherapy. PC NDs were prepared through reprecipitation method without using any additional carriers. The PC NDs were preferentially taken up by TNBC cells and we also observed pH-related drug release. Compared with free PTX and simple PTX/Cur mixture, PC NDs have shown higher therapeutic efficiency and better prognosis while the metastasis rate was significantly lower than that of either PTX or PTX/Cur mix group. Therefore, the self-assembly engineered PC NDs might be a promising nanodrugs for efficient and safe TNBC chemotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Nanobiotechnology, a section of the journal Frontiers in Bioengineering and Biotechnology
Qianyu Zhang, Chongqing University, China
Reviewed by:Jinfeng Liao, Sichuan University, China
Edited by:Jinbing Xie, Southeast University, China
ISSN:2296-4185
2296-4185
DOI:10.3389/fbioe.2021.747637